RSS-Feed abonnieren
DOI: 10.1055/s-2007-980067
Wenn Arzneimittel nicht eingenommen werden - der Einfluss verschiedener Antipsychotika auf das Complianceverhalten schizophrener Patienten
If Drugs are not Taken - How Different Antipsychotics Influence Compliance of Schizophrenic PatientsPublikationsverlauf
Publikationsdatum:
19. Juli 2007 (online)

Zusammenfassung
Der Erfolg einer Arzneimitteltherapie wird unter anderem bestimmt vom Ausmaß, in dem Patienten die verordneten Arzneimittel einnehmen. Chronisch kranke Patienten nehmen jedoch im Mittel lediglich die Hälfte der Arzneimittel wie verordnet ein. Besonders bei schizophrenen Patienten, die meist langjährig Antipsychotika einnehmen müssen, sind die Complianceraten niedrig. Bisher konnten nur wenige eindeutige Faktoren identifiziert werden, die zu Noncompliance führen oder das Complianceverhalten beeinflussen. Atypische Antipsychotika werden ebenso wie Depotformulierungen oft mit einer verbesserten Compliance in Zusammenhang gebracht. In unserer systematischen Literaturrecherche konnten wir keinen Beleg für den häufig beworbenen Unterschied in Complianceraten zwischen atypischen und typischen Antipsychotika finden. Der Einsatz von Depotpräparaten hat den Vorteil, dass noncompliante Patienten einfach identifizierbar sind und so Interventionen gezielt eingesetzt werden können.
Abstract
The effectiveness of pharmacotherapy partly depends on patients’ compliance. However noncompliance with pharmacotherapy occurs frequently. It is particularly a problem in diseases requiring long-term treatment. On average chronically ill patients only take about half of their medication as prescribed. Especially patients with chronic psychiatric diseases, such as schizophrenia, are known to have low compliance rates. Atypical antipsychotics or depot medication are believed to improve compliance. In our systematic literature review we identified ten studies analysing the differences in compliance rates between atypical and typical antipsychotics. However our analyses did not show a difference in compliance rates except for clozapine. The higher compliance rates for clozapine might be explained by the regular monitoring and thus frequent patient contact. A positive effect of depot antipsychotics on compliance could be explained by the easy detection of noncompliant patients.
Schlüsselwörter
Compliance - Schizophrenie - Antipsychotika - Arzneimitteltherapie - Arzneimittelsicherheit
Key words
compliance - schizophrenia - antipsychotic drugs - drug therapy - drug safety
Literatur
- 1
Cramer J, Rosenheck R.
Compliance with medication regimens for mental and physical disorders.
Psychiatr Serv.
1998;
49
196-201
MissingFormLabel
- 2 Haynes R B. Introduction. In: Haynes RB, Taylor DW, and Sackett DL (Hrsg). Compliance in health care. Baltimore, Maryland: The John Hopkins University Press 1979: 1-7
MissingFormLabel
- 3
Osterberg L, Blaschke T.
Adherence to medication.
N Engl J Med.
2005;
353
487-497
MissingFormLabel
- 4
Vermeire E, Hearnshaw H, Royen P Van, Denekens J.
Patient adherence to treatment: three decades of research. A comprehensive review.
J Clin Pharm Ther.
2001;
26
331-342
MissingFormLabel
- 5
Lacro J P, Dunn L B, Dolder C R, Leckband S G, Jeste D V.
Prevalence of and risk factors for medication: nonadherence in patients with schizophrenia.
J Clin Psychiatry.
2002;
63
892-909
MissingFormLabel
- 6
Adams C E, Fenton M K, Quraishi S, David A S.
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.
Br J Psychiatry.
2001;
179
290-299
MissingFormLabel
- 7
Swartz M S, Swanson J W, Wagner H R, Burns B J, Hiday V A.
Effects of involuntary outpatient commitment and depot antipsychotics on treatment
adherence in persons with severe mental illness.
J Nerv ment Dis.
2001;
189
583-592
MissingFormLabel
- 8
Davis J M, Metalon L, Watanabe M D, Blake L.
Depot antipsychotic drugs. Place in therapy.
Drugs.
1994;
47
741-773
MissingFormLabel
- 9
Fenton W S, Blyler C R, Heinssen R K.
Determinants of medication compliance in schizophrenia: empirical and clinical findings.
Schizophr Bull.
1997;
23
637-651
MissingFormLabel
- 10
Otte C, Naber D.
Compliance in der Therapie mit Neuroleptika, Antidepressiva und Lithium.
Bundesgesundheitsblatt.
2001;
44
14-19
MissingFormLabel
- 11
Citrome L, Volavka J.
The promise of atypical antipsychotics fewer side effects mean enhanced compliance
and improved functioning.
Postgraduate Medicine.
2004;
116
Issue 4
MissingFormLabel
- 12
Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A.
Switching from conventional to novel antipsychotic drugs: results of a prospective
naturalistic study.
Schizophr Res.
2002;
57
201-208
MissingFormLabel
- 13
Valenstein M, Blow F C, Copeland L A, McCarthy J F, Zeber J E, Gillon L, Bingham C R, Stavenger T.
Poor antipsychotic adherence among patients with schizophrenia: medication and patient
factors.
Schizophr Bull.
2004;
30
255-264
MissingFormLabel
- 14
Dolder C R, Lacro J P, Dunn L B, Jeste D V.
Antipsychotic medication adherence: Is there a difference between typical and atypical
agents?.
Am J Psychiatry.
2002;
159
103-108
MissingFormLabel
- 15
Olfson M, Mechanic D, Hansell S, Boyer C A, Weiden P J.
Predicting medication noncompliance after hospital discharge among patients with schizophrenia.
Psychiatr Serv.
2000;
51
216-222
MissingFormLabel
- 16
Gilmer T P, Dolder C R, Lacro J P, Folsom D P, Lindamer L, Garcia P, Jeste D V.
Adherence to treatment with antipsychotic medication and health care costs among medicaid
beneficiaries with schizophrenia.
Am J Psychiatry.
2004;
161
692-699
MissingFormLabel
- 17
Diaz E, Neuse E, Sullivan M C, Pearsall H R, Woods S W.
Adherence to conventional and atypical antipsychotics after hospital discharge.
J Clin Psychiatry.
2004;
65
354-360
MissingFormLabel
- 18
Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D.
Medication continuation and compliance: a comparison of patients treated with clozapine
and haloperidol.
J Clin Psychiatry.
2000;
61
382-386
MissingFormLabel
- 19
Rijcken C AW, Tobi H, Vergouwen A CM, de Jong-van den Berg L TW.
Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients`
compliance by using computerised data.
Pharmacoepidemiology and Drug Safety.
2004;
13
365-370
MissingFormLabel
- 20
Menzin J, Boulanger L, Friedman M, Mackell J, LLoyd J R.
Treatment adherence associated with conventional and atypical antipsychotics in a
large state medicaid program.
Psychiatr Serv.
2003;
54
719-723
MissingFormLabel
- 21
Csernansky J G, Mahmoud R, Brenner R.
A comparison of risperidone and haloperidol for the prevention of relapse in patients
with schizophrenia.
N Engl J Med.
2002;
346
16-22
MissingFormLabel
- 22
Grunebaum M F, Weiden P J, Olfson M.
Medication supervision and adherence of persons with psychotic disorders in residential
treatment settings: a pilot study.
J Clin Psychiatry.
2001;
62
394-399
MissingFormLabel
- 23
Thieda P, Beard S, Richter A, Kane J.
An economic review of compliance with medication therapy in the treatment of schizophrenia.
Psychiatr Serv.
2003;
54
508-516
MissingFormLabel
- 24
Vanelli M, Burstein P, Cramer J.
Refill patterns of atypical and conventional antipsychotic medications at a national
retail pharmacy chain.
Psychiatr Serv.
2001;
52
1248-1250
MissingFormLabel
- 25
Lieberman J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O, Keefe R S, Davis S M, Davis C E, Lebowitz B D, Severe J, Hsiao J K.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
N Engl J Med.
2005;
353
1209-1223
MissingFormLabel
- 26
McDonald H P, Garg A X, Haynes R B.
Interventions to enhance patient adherence to medication prescriptions.
JAMA.
2002;
288
2868-2879
MissingFormLabel
- 27
Kyngas H, Duffy M E, Kroll T.
Conceptual analysis of compliance.
J Clin Nurs.
2000;
9
5-12
MissingFormLabel
Dr. Katja Taxis
Department of Pharmacotherapy and Pharmaceutical Care University of Groningen
Ant. Deusinglaan 1
9713 AV Groningen
Niederlande
eMail: k.taxis@rug.nl